Sustainable Growth Advisers LP trimmed its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 995,737 shares of the biopharmaceutical company’s stock after selling 14,047 shares during the period. Regeneron Pharmaceuticals comprises about 4.5% of Sustainable Growth Advisers LP’s holdings, making the stock its 5th largest position. Sustainable Growth Advisers LP’s holdings in Regeneron Pharmaceuticals were worth $402,317,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its stake in shares of Regeneron Pharmaceuticals by 12.7% in the second quarter. Janus Henderson Group PLC now owns 1,802,740 shares of the biopharmaceutical company’s stock valued at $621,927,000 after buying an additional 203,306 shares in the last quarter. Polen Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 4.5% in the second quarter. Polen Capital Management LLC now owns 1,483,634 shares of the biopharmaceutical company’s stock valued at $511,839,000 after buying an additional 64,493 shares in the last quarter. Northern Trust Corp lifted its stake in shares of Regeneron Pharmaceuticals by 2.0% in the second quarter. Northern Trust Corp now owns 934,245 shares of the biopharmaceutical company’s stock valued at $322,306,000 after buying an additional 17,931 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of Regeneron Pharmaceuticals by 53.5% in the third quarter. First Trust Advisors LP now owns 288,480 shares of the biopharmaceutical company’s stock valued at $116,557,000 after buying an additional 100,492 shares in the last quarter. Finally, Morgan Stanley lifted its stake in shares of Regeneron Pharmaceuticals by 0.4% in the second quarter. Morgan Stanley now owns 272,367 shares of the biopharmaceutical company’s stock valued at $93,963,000 after buying an additional 1,127 shares in the last quarter. 66.17% of the stock is currently owned by hedge funds and other institutional investors.

REGN has been the topic of a number of recent analyst reports. Cantor Fitzgerald raised their price target on shares of Regeneron Pharmaceuticals to $441.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. SunTrust Banks reissued a “hold” rating and set a $400.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 3rd. ValuEngine raised shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 6th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 2nd. Finally, Leerink Swann raised their price target on shares of Regeneron Pharmaceuticals from $506.00 to $512.00 and gave the company an “outperform” rating in a research report on Monday, October 1st. Two analysts have rated the stock with a sell rating, seventeen have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $410.95.

Shares of REGN stock opened at $346.56 on Tuesday. The stock has a market capitalization of $38.54 billion, a price-to-earnings ratio of 25.84, a P/E/G ratio of 1.24 and a beta of 1.34. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04. Regeneron Pharmaceuticals Inc has a 52 week low of $281.89 and a 52 week high of $416.49.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 EPS for the quarter, topping the consensus estimate of $4.94 by $0.93. The business had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.64 billion. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.99 earnings per share. Research analysts predict that Regeneron Pharmaceuticals Inc will post 19.31 earnings per share for the current year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, September 24th. The shares were sold at an average price of $388.65, for a total value of $777,300.00. Following the sale, the director now owns 13,000 shares of the company’s stock, valued at $5,052,450. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 22nd. The stock was sold at an average price of $380.49, for a total transaction of $570,735.00. Following the completion of the sale, the director now directly owns 1,500 shares in the company, valued at approximately $570,735. The disclosure for this sale can be found here. In the last ninety days, insiders sold 110,052 shares of company stock worth $44,651,762. Insiders own 12.42% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The correct version of this report can be viewed at https://www.thecerbatgem.com/2018/11/13/regeneron-pharmaceuticals-inc-regn-is-sustainable-growth-advisers-lps-5th-largest-position.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also: What is a Fiduciary?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.